Testosterone replacement therapy and the risk of prostate cancer - 0 views
www.ncbi.nlm.nih.gov/...PMC4814970
Testosterone testosterone therapy saturation theory cancer prostate cancer male hormones
shared by Nathan Goodyear on 01 Oct 16
- No Cached
-
When the level of circulating androgen is below normal, some androgen receptors are inactive, and the secondary downstream effects are decreased. Once androgen receptors within the prostate are saturated, however, increasing testosterone will no longer have an effect
-
Only the subset of individuals with pretreatment testosterone level <250 ng dl−1 had PSA level correlating with free and total testosterone level
- ...7 more annotations...
-
none of the men stopped testosterone supplementation due to prostate cancer recurrence, and none demonstrated cancer progression
-
PSA level did transiently rise in one patient; however, none exceeded a PSA of 1.5 ng ml−1 to raise concern for biochemical recurrence
-
after 19 months on TRT, 10 hypogonadal patients with a history of undergoing a radical retropubic prostatectomy for prostate cancer had no PSA recurrence and had statistically significant improvements in serum total testosterone and hypogonadal symptoms
-
Similarly, Kaufman and Graydon14 examined case records of seven hypogonadal men who had undergone curative RP with symptoms of hypogonadism and low serum testosterone levels treated with testosterone replacement. No biochemical or clinical evidence of cancer recurrence was noted
-
In a much larger case series, Khera et al.15 reviewed the records of 57 men who received TRT following RP. After an average of 36 months following RP, testosterone replacement was initiated and followed for an average of 13 months. Mean testosterone values rose significantly and once again, there was no increase in PSA values and, therefore, no diagnosed biochemical recurrence
-
Four of the patients in the treatment group were found to have cancer recurrence, compared with eight in the control group